Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
NEWARK, Calif., Jan. 27, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will hold an Analyst and Investor Day in New York City on Wednesday, March 23, 2016 from 9:00 a.m. ET – 11:30 a.m. ET (6:00 a.m. PT – 8:30 a.m. PT). Depomed’s President and Chief Executive Officer Jim Schoeneck and members of the company's management team will be joined by Joseph V. Pergolizzi, Jr., MD, an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and an internationally recognized leader in the area of pain medicine and management. The event will provide a business overview as well as a review of the marketed and development-stage product pipeline.
Space is limited and attendance is by invitation only. The presentations, as well as the question and answer session, will be webcast and will be accessible via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days. Additional event details will be available closer to the event date.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
